108 related articles for article (PubMed ID: 36776006)
1. [Establishment and preliminary application of organoids in ovarian cancer].
Zhang L; Meng HY; Zhang YS; Miao HX; Yuan L; Zhou SL; Jiang Y; Wan YC; Cheng WW
Zhonghua Fu Chan Ke Za Zhi; 2023 Feb; 58(2):112-120. PubMed ID: 36776006
[No Abstract] [Full Text] [Related]
2. Ex vivo chemosensitivity assay using primary ovarian cancer organoids for predicting clinical response and screening effective drugs.
Ito Y; Kondo J; Masuda M; Matsuzaki S; Onuma K; Kanda M; Watanabe Y; Sakaguchi H; Yoshino K; Ueda Y; Kamiura S; Kimura T; Inoue M
Hum Cell; 2023 Mar; 36(2):752-761. PubMed ID: 36474106
[TBL] [Abstract][Full Text] [Related]
3. Using genetically encoded fluorescent biosensors to interrogate ovarian cancer metabolism.
Bose S; Yao H; Huang Q; Whitaker R; Kontos CD; Previs RA; Shen X
J Ovarian Res; 2022 Oct; 15(1):114. PubMed ID: 36266675
[TBL] [Abstract][Full Text] [Related]
4. The Anti-Tumor Effect of Nab-Paclitaxel Proven by Patient-Derived Organoids.
Xiao X; Chen W; Wei ZW; Chu WW; Lu XF; Li B; Chen H; Meng SJ; Hao TF; Wei JT; He YL; Zhang CH
Onco Targets Ther; 2020; 13():6017-6025. PubMed ID: 32612367
[TBL] [Abstract][Full Text] [Related]
5. Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells.
Kijima T; Nakagawa H; Shimonosono M; Chandramouleeswaran PM; Hara T; Sahu V; Kasagi Y; Kikuchi O; Tanaka K; Giroux V; Muir AB; Whelan KA; Ohashi S; Naganuma S; Klein-Szanto AJ; Shinden Y; Sasaki K; Omoto I; Kita Y; Muto M; Bass AJ; Diehl JA; Ginsberg GG; Doki Y; Mori M; Uchikado Y; Arigami T; Avadhani NG; Basu D; Rustgi AK; Natsugoe S
Cell Mol Gastroenterol Hepatol; 2019; 7(1):73-91. PubMed ID: 30510992
[TBL] [Abstract][Full Text] [Related]
6. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
7. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
8. Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance.
Gorski JW; Zhang Z; McCorkle JR; DeJohn JM; Wang C; Miller RW; Gallion HH; Dietrich CS; Ueland FR; Kolesar JM
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440225
[TBL] [Abstract][Full Text] [Related]
9. Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapy.
Wang Y; Wang Y; Zheng W
Int J Clin Exp Pathol; 2013; 6(10):2121-8. PubMed ID: 24133590
[TBL] [Abstract][Full Text] [Related]
10. Establishment of gastric cancer organoid and its application in individualized therapy.
Miao X; Wang C; Chai C; Tang H; Hu J; Zhao Z; Luo W; Zhang H; Zhu K; Zhou W; Xu H
Oncol Lett; 2022 Dec; 24(6):447. PubMed ID: 36420067
[TBL] [Abstract][Full Text] [Related]
11. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
de Witte CJ; Espejo Valle-Inclan J; Hami N; Lõhmussaar K; Kopper O; Vreuls CPH; Jonges GN; van Diest P; Nguyen L; Clevers H; Kloosterman WP; Cuppen E; Snippert HJG; Zweemer RP; Witteveen PO; Stelloo E
Cell Rep; 2020 Jun; 31(11):107762. PubMed ID: 32553164
[TBL] [Abstract][Full Text] [Related]
12. Advantages and limitations of 3D organoids and ex vivo tumor tissue culture in personalized medicine for prostate cancer.
Mickova A; Morong M; Levková M; Kurfúrstová D; Kharaishvili G; Überall I; Student V; Student V; Drapela S; Soucek K; Bouchal J
Klin Onkol; 2022; 35(6):473-481. PubMed ID: 36513514
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers.
Singh T; Neal A; Dibernardo G; Raheseparian N; Moatamed NA; Memarzadeh S
Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35191515
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues.
Tamura H; Higa A; Hoshi H; Hiyama G; Takahashi N; Ryufuku M; Morisawa G; Yanagisawa Y; Ito E; Imai JI; Dobashi Y; Katahira K; Soeda S; Watanabe T; Fujimori K; Watanabe S; Takagi M
Oncol Rep; 2018 Aug; 40(2):635-646. PubMed ID: 29917168
[TBL] [Abstract][Full Text] [Related]
15. An experimental model for ovarian cancer: propagation of ovarian cancer initiating cells and generation of ovarian cancer organoids.
Chen YA; Lu CY; Cheng WF; Kuo KT; Yu CW; Ho HN; Chen HF; Pan SH
BMC Cancer; 2022 Sep; 22(1):967. PubMed ID: 36085021
[TBL] [Abstract][Full Text] [Related]
16. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
17. Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies.
Lee JH; Kim H; Lee SH; Ku JL; Chun JW; Seo HY; Kim SC; Paik WH; Ryu JK; Lee SK; Lowy AM; Kim YT
Gut Liver; 2022 Jul; 16(4):625-636. PubMed ID: 34916338
[TBL] [Abstract][Full Text] [Related]
18. Formation and optimization of three-dimensional organoids generated from urine-derived stem cells for renal function in vitro.
Sun G; Ding B; Wan M; Chen L; Jackson J; Atala A
Stem Cell Res Ther; 2020 Jul; 11(1):309. PubMed ID: 32698872
[TBL] [Abstract][Full Text] [Related]
19. [Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro].
Zhang SL; Jiang T; Lin B; Zhao CQ; Meng LR
Zhonghua Fu Chan Ke Za Zhi; 2004 Jul; 39(7):482-5. PubMed ID: 15347474
[TBL] [Abstract][Full Text] [Related]
20. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Kopper O; de Witte CJ; Lõhmussaar K; Valle-Inclan JE; Hami N; Kester L; Balgobind AV; Korving J; Proost N; Begthel H; van Wijk LM; Revilla SA; Theeuwsen R; van de Ven M; van Roosmalen MJ; Ponsioen B; Ho VWH; Neel BG; Bosse T; Gaarenstroom KN; Vrieling H; Vreeswijk MPG; van Diest PJ; Witteveen PO; Jonges T; Bos JL; van Oudenaarden A; Zweemer RP; Snippert HJG; Kloosterman WP; Clevers H
Nat Med; 2019 May; 25(5):838-849. PubMed ID: 31011202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
